紫杉烷类抗肿瘤药物剂量个体化研究进展

Research progress on dose individualization of the taxanes chemotherapeutic drugs

紫杉烷类药物是治疗实体肿瘤的常用药物,临床常基于体表面积(body surface area,BSA)给药,但其无法降低个体间代谢差异以及化疗产生的毒副反应,已不再是最适宜的剂量算法,有必要对紫杉烷类药物采用剂量个体化给药。因此,现就紫杉烷类药物的代谢酶活性测定和治疗药物监测(TDM)的研究进展进行归纳和总结,以期为紫杉烷类药物剂量个体化的理论研究及临床应用提供参考。

Taxanes are commonly used in the treatment of solid tumors.It is often based on the body surface area(BSA),but BSA can not reduce the metabolic differences between individuals and the side effects of chemotherapy.It is no longer the most appropriate dose algorithm,so it is necessary to use dose individualized administration for taxanes.Therefore,we reviewed the research progress in the measurement of metabolic enzyme activity of taxanes and the monitoring of therapeutic drugs(TDM),in order to provide reference for the theoretical research and clinical application of dose individualization of taxanes.